90
Participants
Start Date
June 25, 2012
Primary Completion Date
January 31, 2024
Study Completion Date
December 31, 2024
PZP115891, PCI-24781
"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
University of California, San Francisco, San Francisco
Collaborators (2)
Pharmacyclics LLC.
INDUSTRY
Novartis
INDUSTRY
Xynomic Pharmaceuticals, Inc.
INDUSTRY
GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
UNKNOWN
Pamela Munster
OTHER